Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Soumerai JD, Thompson MC, Dogan A, Seshan VE, Flaherty K, Slupe N, Carter J, Hochberg E, Barnes JA, Abramson JS, Noy A, Owens CN, Palomba ML, Kumar A, Roeker LE, Takvorian RW, Epstein-Peterson ZD, Geyer MB, Salles GA, Stuver RN, Caron PC, Islam P, Haque T, Ghione P, Steiner RE, Torka P, David KA, Lue JK, Hamlin PA, Moskowitz AJ, Falchi L, Haydu JE, Johnson PC, Mi J, Mahajan N, Pendleton J, Labarre A, Chabowska M, Choma M, Grieve C, Joseph A, Dorsey C, Brutus J, Martignetti R, Nazzaro R, Coyle J, Maas OG, Meemanage Z, Simkins E, Kakolu A, Gordan C, Baez E, Beatty B, Apazidis A, Gulotta M, Ratcliff S, Hirata J, Shahkarami M, Jacob AP, Abdel-Wahab O, Zelenetz AD

Open source

DOI: 10.1182/bloodadvances.2026020221
Published: 2026 Jun 30
Container: Blood advances
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2026020221,
  title = {Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.},
  author = {Soumerai JD and Thompson MC and Dogan A and Seshan VE and Flaherty K and Slupe N and Carter J and Hochberg E and Barnes JA and Abramson JS and Noy A and Owens CN and Palomba ML and Kumar A and Roeker LE and Takvorian RW and Epstein-Peterson ZD and Geyer MB and Salles GA and Stuver RN and Caron PC and Islam P and Haque T and Ghione P and Steiner RE and Torka P and David KA and Lue JK and Hamlin PA and Moskowitz AJ and Falchi L and Haydu JE and Johnson PC and Mi J and Mahajan N and Pendleton J and Labarre A and Chabowska M and Choma M and Grieve C and Joseph A and Dorsey C and Brutus J and Martignetti R and Nazzaro R and Coyle J and Maas OG and Meemanage Z and Simkins E and Kakolu A and Gordan C and Baez E and Beatty B and Apazidis A and Gulotta M and Ratcliff S and Hirata J and Shahkarami M and Jacob AP and Abdel-Wahab O and Zelenetz AD},
  year = {2026},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2026020221},
  url = {https://doi.org/10.1182/bloodadvances.2026020221}
}

RIS

TY  - JOUR
TI  - Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.
AU  - Soumerai JD
AU  - Thompson MC
AU  - Dogan A
AU  - Seshan VE
AU  - Flaherty K
AU  - Slupe N
AU  - Carter J
AU  - Hochberg E
AU  - Barnes JA
AU  - Abramson JS
AU  - Noy A
AU  - Owens CN
AU  - Palomba ML
AU  - Kumar A
AU  - Roeker LE
AU  - Takvorian RW
AU  - Epstein-Peterson ZD
AU  - Geyer MB
AU  - Salles GA
AU  - Stuver RN
AU  - Caron PC
AU  - Islam P
AU  - Haque T
AU  - Ghione P
AU  - Steiner RE
AU  - Torka P
AU  - David KA
AU  - Lue JK
AU  - Hamlin PA
AU  - Moskowitz AJ
AU  - Falchi L
AU  - Haydu JE
AU  - Johnson PC
AU  - Mi J
AU  - Mahajan N
AU  - Pendleton J
AU  - Labarre A
AU  - Chabowska M
AU  - Choma M
AU  - Grieve C
AU  - Joseph A
AU  - Dorsey C
AU  - Brutus J
AU  - Martignetti R
AU  - Nazzaro R
AU  - Coyle J
AU  - Maas OG
AU  - Meemanage Z
AU  - Simkins E
AU  - Kakolu A
AU  - Gordan C
AU  - Baez E
AU  - Beatty B
AU  - Apazidis A
AU  - Gulotta M
AU  - Ratcliff S
AU  - Hirata J
AU  - Shahkarami M
AU  - Jacob AP
AU  - Abdel-Wahab O
AU  - Zelenetz AD
PY  - 2026
JO  - Blood advances
DO  - 10.1182/bloodadvances.2026020221
UR  - https://doi.org/10.1182/bloodadvances.2026020221
ER  -

APA

JD, S., MC, T., A, D., VE, S., K, F., N, S., J, C., E, H., JA, B., JS, A., A, N., CN, O., ML, P., A, K., LE, R., RW, T., ZD, E., MB, G., GA, S., RN, S., PC, C., P, I., T, H., P, G., RE, S., P, T., KA, D., JK, L., PA, H., AJ, M., L, F., JE, H., PC, J., J, M., N, M., J, P., A, L., M, C., M, C., C, G., A, J., C, D., J, B., R, M., R, N., J, C., OG, M., Z, M., E, S., A, K., C, G., E, B., B, B., A, A., M, G., S, R., J, H., M, S., AP, J., O, A., & AD, Z. (2026). Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.. Blood advances. https://doi.org/10.1182/bloodadvances.2026020221

Source records

pubmed · retrieved 2026-09-26T18:23:15.350Z